AVITA Medical reaches 52-week high and AVITA Medical stock trades 2.62 percent higher
Published on 10/06/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AVITA Medical (ISIN AU000000AVH4) reached a 52-week high of USD 12.76 on October 2, 2026, while its stock was trading at EUR 2.35 at Lang & Schwarz on October 6, 2026, plus 2.62 percent versus the prior close of EUR 2.29. RTTNews reported the high on October 5, 2026.
Revenue growth supports the outlook
AVITA reported revenue of USD 21.70 million in the second quarter of 2026, an 18 percent increase from the year-earlier period. The figure exceeded the USD 20.25 million consensus estimate, while adjusted loss per share was USD 0.25 against an expected USD 0.29 loss, according to MarketBeat in its September 13, 2026 report.
AVITA raised its 2026 revenue outlook to USD 86 million to USD 89 million from USD 80 million to USD 85 million. Management also expects cash flow breakeven in the fourth quarter of 2026, a milestone highlighted in the Investing.com transcript published September 16, 2026.
Execution remains the key test
The Morgan Stanley conference discussion placed the commercial emphasis on deeper use within existing accounts rather than rapid geographic expansion. AVITA said it serves about 200 accounts, including 125 burn centers and 60 to 70 trauma centers, while 25 accounts use its full three-product portfolio.
The company also cited an 86 percent gross margin for RECELL and expects overall gross margin to remain above 80 percent. That margin profile gives the revenue outlook operating leverage, but reimbursement and execution problems from 2025 remain part of the company narrative, as reported by Investing.com.
RCEL price and trading snapshot
RCEL was trading at EUR 2.35 at Lang & Schwarz on October 6, 2026 at 2:14 p.m. CEST, up 2.62 percent versus the Lang & Schwarz prior close of EUR 2.29 on October 5, 2026. The primary listing is Nasdaq, where the finance snapshot showed USD 13.25 on October 5, 2026 at 4:00 p.m. ET.
AVITA Medical market facts
- Company: AVITA Medical, Inc.
- ISIN: AU000000AVH4
- Ticker: RCEL
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 6, 2026, 2:14 p.m. CEST): EUR 2.35
- Change versus prior close: plus 2.62 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 2.29
- Market capitalization: USD 329.2 million (as of October 5, 2026)
- 52-week range: USD 3.22-13.48 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Devices
